CHA₂DS₂-VASc and CHA₂DS₂-VA Score Calculator
CHA₂DS₂-VASc and CHA₂DS₂-VA Score Calculator
Stroke risk in atrial fibrillation on either convention. The 2024 ESC guideline dropped the sex category and moved to CHA₂DS₂-VA; the two age items are alternatives, so the real maximum is 9, not the 10 the weights add up to.
CHA₂DS₂-VASc and CHA₂DS₂-VA Score
7 items → 0–9 or 0–872-year-old woman with hypertension and diabetes, no heart failure, no prior stroke, no vascular disease — CHA₂DS₂-VASc convention
Scoring
CHA₂DS₂-VA = the same items without the sex category
Maximum 9 and 8 respectively — the two age items cannot both be scored
- 9, not 10
- the individual weights sum to 10, but age ≥75 and age 65–74 are alternatives, so no patient can score both. The true maximum is 9 for CHA₂DS₂-VASc and 8 for CHA₂DS₂-VA. Several widely used calculators and review articles quote 10 and 9, which is the sum of the weights rather than the highest achievable score
- the two doubled letters
- age 75 or over scores 2 and previous stroke, TIA or arterial thromboembolism scores 2. Everything else scores 1. A prior stroke and advanced age together already reach the treatment threshold twice over
- the 2024 ESC change
- the guideline dropped the sex category, citing the complication it introduces into practice and the exclusion of people who are non-binary or transgender or on sex hormone therapy. The recommendation to anticoagulate at ≥2 stayed Class I but its Level of Evidence fell from A in 2020 to C in 2024
- the thresholds are the same arithmetic
- 2020 ESC on CHA₂DS₂-VASc: Class I at ≥2 in men and ≥3 in women. 2024 ESC on CHA₂DS₂-VA: Class I at ≥2. For a woman, VA = VASc − 1, so ≥3 on VASc and ≥2 on VA select exactly the same people. The change simplifies the score without changing who is treated
Worked example
72-year-old woman with hypertension and diabetes, no heart failure, no prior stroke, no vascular disease — CHA₂DS₂-VASc convention
Hypertension 1 + age 65–74 1 + diabetes 1 + female sex 1 = 4 points
Age 65–74 scores 1. Had she been 76 that item would score 2, not 3 — the two age bands are alternatives, which is why the maximum is 9 and not 10
4 is at or above the female CHA₂DS₂-VASc threshold of 3, so oral anticoagulation is recommended
On CHA₂DS₂-VA the same patient scores 3, because the sex point is dropped — still at or above the 2024 ESC threshold of 2, and the same decision
That equivalence holds generally: for a woman, CHA₂DS₂-VA is CHA₂DS₂-VASc minus one, and the ESC threshold fell by one at the same time
The items and their weights
| Letter | Criterion | Points | In CHA₂DS₂-VA? |
|---|---|---|---|
| C | Congestive heart failure or left ventricular dysfunction | 1 | Yes |
| H | Hypertension | 1 | Yes |
| A₂ | Age 75 or over | 2 | Yes |
| D | Diabetes mellitus | 1 | Yes |
| S₂ | Previous stroke, TIA or thromboembolism | 2 | Yes |
| V | Vascular disease — prior MI, peripheral arterial disease, aortic plaque | 1 | Yes |
| A | Age 65–74 | 1 | Yes |
| Sc | Sex category — female | 1 | No — dropped in 2024 |
Two conventions, one decision
| CHA₂DS₂-VASc — 2020 ESC | CHA₂DS₂-VA — 2024 ESC | |
|---|---|---|
| Maximum score | 9 | 8 |
| Anticoagulation recommended (Class I) | ≥2 in men, ≥3 in women | ≥2, regardless of sex |
| Anticoagulation should be considered (Class IIa) | 1 in men, 2 in women | 1, regardless of sex |
| Level of evidence for the Class I recommendation | A | C |
| Who else uses it | NICE, and guidelines outside Europe, which have not adopted CHA₂DS₂-VA | The 2024 ESC guideline |
| Effect on who gets anticoagulated | — | None. For a woman VA = VASc − 1 and the threshold also fell by 1 |
The same patients, counted two ways
CHA₂DS₂-VASc estimates the annual risk of stroke and systemic embolism in atrial fibrillation, and it is used to decide who is anticoagulated. Six of its items score one point and two score two — age 75 or over, and a previous stroke, transient ischaemic attack or arterial thromboembolism. The individual weights add up to 10, but no patient can reach that, because the two age criteria are alternatives: you are 75 or over, or 65 to 74, or neither. The achievable maximum is 9. Calculators that let both age boxes be ticked, and review articles that quote a maximum of 10, are adding weights rather than scoring patients.
In 2024 the European Society of Cardiology moved to CHA₂DS₂-VA, dropping the sex category and taking the maximum to 8. The stated reasoning was practical rather than epidemiological: including sex complicates the decision for clinicians and patients, and a binary sex item has no clean answer for people who are non-binary or transgender or taking sex hormone therapy. The recommendation to anticoagulate at a score of 2 or more remains Class I, but its Level of Evidence fell from A in the 2020 guideline to C in 2024, which is an honest acknowledgement that the change rests on expert consensus rather than new trials.
This is a genuine divergence between guidelines and should be read as one: NICE and the guidelines outside Europe have not adopted CHA₂DS₂-VA. What makes the divergence less alarming than it looks is arithmetic. The 2020 CHA₂DS₂-VASc thresholds were sex-specific — Class I at 2 or more in men and 3 or more in women — and for a woman CHA₂DS₂-VA is simply CHA₂DS₂-VASc minus one. A threshold that also fell by one therefore selects exactly the same people. The two conventions produce different numbers and the same decision.
The dangerous version is the hybrid: a CHA₂DS₂-VASc total read against a flat threshold of 2 with no sex adjustment, which anticoagulates women whose only risk factor is being female. That is what dropping the item was meant to prevent. Whichever convention is used, the score is a starting point for a conversation and not a rule — it says nothing about renal function, frailty, falls, adherence or what matters to the person in front of you, and bleeding risk should be assessed alongside it to find what can be corrected rather than to decide whether to treat at all.
Frequently asked questions
What is the maximum CHA₂DS₂-VASc score?
Nine. The individual weights sum to 10, but the two age criteria are mutually exclusive — a patient scores 2 for being 75 or over, or 1 for being 65 to 74, and never both. CHA₂DS₂-VA, which drops the sex category, has a maximum of 8.
What is the difference between CHA₂DS₂-VASc and CHA₂DS₂-VA?
CHA₂DS₂-VA is CHA₂DS₂-VASc without the sex category. The 2024 ESC atrial fibrillation guideline adopted it because including sex complicates the decision and excludes people who are non-binary or transgender. The clinical items and their weights are otherwise identical.
Does dropping the sex category change who gets anticoagulated?
No. The 2020 CHA₂DS₂-VASc thresholds were sex-specific — Class I at 2 or more in men and 3 or more in women — and for a woman CHA₂DS₂-VA is CHA₂DS₂-VASc minus one. The 2024 threshold of 2 or more selects exactly the same patients.
Why did the level of evidence fall from A to C?
Because the 2024 change to CHA₂DS₂-VA rests on expert consensus rather than on new randomised evidence. The recommendation to anticoagulate at a score of 2 or more is still Class I, but the guideline grades the evidence behind the revised score as Level C rather than the Level A carried in 2020.
Should a woman with no other risk factors be anticoagulated?
Not on the score alone. Female sex on its own gives a CHA₂DS₂-VASc of 1, below the female Class I threshold of 3 and below the Class IIa threshold of 2, and a CHA₂DS₂-VA of 0. Applying a flat threshold of 2 to a woman’s CHA₂DS₂-VASc score is the error that dropping the item was meant to prevent.
Related calculators
References
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the EACTS. Eur Heart J. 2021;42(5):373–498.
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.